Arzeda Expands Applications of its Protein Design Platform and Advances Towards Commercial Deployment of Designer Enzymes for Sustainable Food & Nutrition Ingredients
Arzeda, the Protein Design Company™, today announced that biotechnology veteran Doug Cameron, PhD has joined the company’s board of directors. Dr. Cameron brings three decades of experience in commercializing food and agriculture biotechnology products.
Arzeda, the Protein Design Company™, today announced that the company has entered into a joint development agreement with Amyris that leverages the complementary nature of the two companies’ technology platforms to accelerate the development and commercialization of high value ingredients. This marks the second joint project between the parties. Amyris and Arzeda collaborated successfully on a Defense Advanced Research Projects Agency (DARPA) Technology Investment Agreement (TIA) during the
BP and Arzeda, the Protein Design Company™, are pleased to announce they have entered a second extended collaboration agreement for developing a bio-process for production of a renewable chemical of high strategic and industrial interest to BP.
Arzeda, the Protein Design Company™, has been featured in the April 6th issue of The Economist’s Technology Quarterly on synthetic biology. Prev post Next post
Arzeda, the Protein Design Company™, has been recognized for the third time as among the top companies in the advanced bioeconomy in the annual rankings by Biofuels Digest, the world’s most widely-read bioeconomy daily. Arzeda was ranked Number 5 in this year’s 40 Hottest Technologies in the Advanced Bioeconomy list, one step above its number 6 ranking in 2017. Arzeda ranked number 27 on the list in 2016.
Arzeda, The Protein Design Company™, and BP announced a collaboration to develop a process for producing a renewable chemical with broad applications. This collaboration will leverage each company’s unique capabilities, with work occurring at Arzeda’s laboratories, as well as at BP’s Biosciences Center.
Arzeda Corp, “The Protein Design Company™,” and TeselaGen Biotechnology Inc., a software company providing automated DNA design solutions with it’s Synthetic Evolution™ software platform, today announced that Arzeda will license TeselaGen’s proprietary cloud-based informatics solution and collaborate to extend TeselaGen’s state-of-the-art biological design automation platform. “TeselaGen’s industry-leading software tools complement our own technology stack. With the deployment
Arzeda, The Protein Design Company™, today announced that it had raised $12 million in a Series A round of funding led by OS Fund and including Bioeconomy Capital and Sustainable Conversion Ventures, as well as a follow-on investment from Arzeda’s seed investor, WRF Capital. Arzeda’s board will be expanded to include Jeff Klunzinger, Co-Founder at OS Fund.
Gen9 and Arzeda today announced an agreement for the supply of megabase quantities of synthetic DNA that will enable Arzeda to accelerate development of novel molecules for its own products as well as those of its partners. The collaboration is part of Gen9’s MAP program, designed to provide industrial users of synthetic DNA with access to game-changing economics for synthetic DNA.